

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-23 (canceled)

Claim 24 (original): A method for reducing hemostasis in a subject, comprising administering to said subject an inhibitor of P-selectin activity, such that procoagulant activity is reduced.

Claim 25 (original): The method of claim 24, wherein the inhibitor of P-selectin activity decreases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claim 26 (original): The method of claim 25, wherein the inhibitor of P-selectin activity decreases the proteolytic cleavage of P-selectin from the cell surface.

Claim 27 (withdrawn)

Claim 28 (withdrawn)

Claim 29 (original): The method of claim 24, wherein the inhibitor of P-selectin activity is recombinant soluble PSGL-1.

Claim 30 (canceled)

Claim 31 (original): A method for treating or preventing a thrombotic disorder in a subject, comprising administering to said subject an inhibitor of P-selectin activity, such that the thrombotic disorder is treated or prevented.

Claim 32 (original): The method of claim 31, wherein said disorder is arteriosclerosis.

Claim 33 (original): The method of claim 31, wherein said disorder is deep vein thrombosis.

Claim 34 (original): The method of claim 31, wherein said disorder is angina.

Claim 35 (canceled)

Claim 36 (original): The method of claim 31, wherein the inhibitor of P-selectin activity decreases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claim 37 (previously amended): A method for modulating hemostatic potential in a subject, comprising administering an inhibitor of P-selectin activity to the subject.

Claim 38 (canceled)

Claim 39 (previously amended): The method of claim 37, wherein the inhibitor of P-selectin activity decreases the level of soluble P-selectin in the plasma of said subject.

Claims 40-50 (canceled)

Claim 51 (withdrawn)

Claim 52 (previously added): The method of claim 24, wherein the inhibitor of P-selectin activity is a peptidomimetic of PSGL-1.

Claim 53 (withdrawn)

Claim 54 (withdrawn)

Claim 55 (currently amended): The method of claim 31, wherein the inhibitor of P-selectin activity is selected from the group consisting of small molecules, peptides, peptidomimetics, and an anti-P selectin antibodies antibody.

Claim 56 (withdrawn)

Claim 57 (withdrawn)

Claim 58 (currently amended): The method of claim 37, wherein the inhibitor of P-selectin activity is selected from the group consisting of small molecules, peptides, antibodies and peptidomimetics a peptidomimetic of PSGL-1.

Claim 59 (withdrawn)

Claim 60 (previously added): The method of claim 37, wherein the inhibitor of P-selectin activity decreases the proteolytic cleavage of P-selectin from the cell surface.

Claim 61 (withdrawn)